Recombinant Human Endostatin Market Industry Insights, Outlook and Forecast 2018-2026

Increasing research and development activities for identifying potential uses of recombinant human endostatin is expected to propel growth of the market. For instance, according to a paper published in the journal Nature, September 2015, a study was conducted to evaluate effects of recombinant human endostatin in combination with radiotherapy for treating esophageal squamous cell carcinoma and to discover its potential mechanisms. These findings suggested that recombinant human endostatin is a potential anti-angiogenic agent in esophageal squamous cell carcinoma mainly when combined with radiotherapy.

Free Request Sample Report @

Furthermore, according to National Center for Biotechnology Information (NCBI) January 2017, recombinant human endostatin in combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) may aid in treatment of Angioimmunoblastic T Cell Lymphoma (AITL), a form of Peripheral T Cell Lymphoma (PTCL). Such novel therapies for PTCL treatment are immediately desired to improve the outcomes of patients with this disease. These factors are expected to propel growth of the recombinant human endostatin market.

North America is expected to hold dominant position in the global recombinant human endostatin market over the forecast period, owing to increasing prevalence of cancer in the U.S. For instance, According to a report by the Centers for Disease Control and Prevention (CDC), around 1,633,390 new cancer cases were reported in the U.S. in 2015 and the number is expected to reach to 1,735,350 in 2018.

Furthermore, Asia Pacific is projected to witness significant growth in the global recombinant human endostatin market during forecast period, owing to increasing number of clinical trials for recombinant human endostatin. For instance, the PLA General Hospital in China is undertaking clinical phase II study for recombinant human endostatin combination with radiotherapy for the treatment of Hepatocellular Carcinoma (HCC). The study started in January 2017 and is estimated to complete in December 2019.

Moreover, Yun-fei Xia University, in China is undergoing clinical phase II study using chemotherapy and Endostar (endostatin). Endostar is administered as an intravenous infusion for the treatment of refractory nasopharyngeal carcinoma. The study started in July 2015 and is expected to complete in December 2020.

Increasing challenges in significant production of recombinant human endostatin is expected to hinder the market growth. For instance, in April 2017, according to a National Center for Biotechnology Information (NCBI) report, tumor treatment needs large quantities of biologically active recombinant human endostatin, which in turn requires production of large quantities of recombinant human endostatin. This process is difficult as it based on recombinant DNA technology and also have low success rates for the treatment of cancer. Furthermore, the cost of recombinant human endostatin is high and it has short half-life. Endostatin is unstable since, endostatin-purification process may denature its structure and the resultant yields may be low.

For More Information On This Report, Please Visit @

Key players operating in the global recombinant human endostatin market include, Pfizer Inc., Novus Biologicals, Biocon, Thermo Fisher Scientific, Yantai Medgenn Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., PeproTech, Inc., Onyx Pharmaceuticals, Inc., Genexine, Inc., Hetero., Intas Pharmaceuticals Ltd., and Novartis AG.

Molecular Imaging Market Future Trend, Outlook and Forecast 2018-2026

Increasing prevalence of various chronic diseases such as cancer and other genetic disorders are propelling demand for early disease diagnosis eventually driving the medical imaging market growth. According to the Centers for Disease Control and Prevention (CDC), February 2018 data, in the U.S., around 22,000 men and 9,000 women suffer from liver cancer, and around 16,000 men and 8,000 women die from liver cancer annually. Molecular imaging has become part of standard care for many types of cancer. The use of imaging techniques in early cancer detection, treatment response, and new therapy development is steadily growing and has already significantly impacted on clinical management of cancer.

Request Sample Report @

Moreover, rising cases of neurological disorders such as Alzheimer’s, which can be easily detected with PET-CT scanner is also contributing to the medical imaging market growth. For instance, according to the Alzheimer’s Association, in 2017, over 5 million people were estimated to be suffering from Alzheimer’s disease, which was also reported to be the sixth-leading cause of death in the U.S. However, some limitations associated with molecular modalities including side effects of radiation and lack of penetration depth, which is expected to confine the molecular imaging market growth to some extent.

Manufacturers are focused on research and development to integrate advanced medical technologies for in vitro diagnosis. For instance, in 2014, Philips Healthcare received the U.S. FDA approval for spectral imaging system (IQon Spectral CT). The IQon Spectral CT is a leading, new, high standard for medical imaging. As per the study conducted by Radiological Society of North America, in 2013, Philips IQon Spectral CT system exhibited enhanced diagnosis in up to 70% cases as compared to conventional imaging methods.

With rapid technological advancements, targeted therapy, presymptomatic detection, and personalized medicine are possible in future with the use multimodal molecular imaging. Moreover, researchers are using molecular imaging to identify the strategies for developing new drugs and to design clinical trials to test their effectiveness. Information provided by molecular imaging technologies has the potential to accelerate the drug development and approval process by making it less expensive and more effective.

However, there are some limitations associated with all molecular imaging modalities, which may restrain molecular imaging market growth. For instance, optical imaging lacks penetration depth, especially when working at visible wavelengths. Depth of penetration is used for the absorption and scattering of light to identify molecular structure.

Moreover, optical imaging and ultrasound do not offer whole body imaging. MRI offers unlimited depth penetration and whole body imaging, however, it is more costly than other modalities. PET-CT imaging is not recommended for all patients due to harmful radiation that causes side effects to the body. For instance, it is not suitable for pregnant women, as the radiation could harm the baby.

For More Information On This Report, Please Visit @

Key players operating in the global molecular imaging market include Carestream Health, Fujifilm Holdings Corporation, GE Healthcare, Hitachi Ltd, Hologic, Inc., Siemens AG, Philips Healthcare, Samsung Medison, Shimadzu Corporation, and Toshiba Medical Systems Corporation. Several players operating in the medical imaging devices market are focusing on improving the image quality, in order to cater to unmet medical imaging needs.

Coronary Stents Market Opportunities, Dynamic, Outlook and Forecast 2018-2026

Increasing product launches coupled with increasing geographical approval in drug eluting coronary stents is propelling growth of the coronary stents market. For instance, in May 2018, Abbott received the U.S. FDA approval for XIENCE Sierra, the new generation of everolimus-eluting coronary stent. The XIENCE received approval from the Japan’s regulatory body in April 2018, and CE mark from European regulatory bodies in 2017. Furthermore, companies are also evaluating and launching products with novel material, such as with metal like cobalt chromium and fully biodegradable stents.

Request Sample Report @

For instance, in 2017, Medtronic received approval for Onyx drug eluting stents from the U.S. FDA for the treatment of coronary artery disease in adults. In the same year, company also received approval for cobalt chromium coronary stent system, known as Pro-Kinetic energy stents after BIOHELIX-I studies.

Furthermore, in 2017, Cordis launched two products: the Tryton Side Branch Stent and Medinol’s NIRxcell, a cobalt-chromium bare metal stent (BMS) under comprehensive interventional cardiology portfolio at 29th Transcatheter Cardiovascular Therapeutics Symposium. Such product launches in symposiums and conferences are expected to highlight the product and its features to healthcare professionals and distributors, in turn aiding in increasing the customer base of the company.

Mergers and acquisition by key players are further augmenting the coronary stents market growth with major players enhancing their market share and leveraging the strengths of the acquired company. For instance, in February 2018, Stentys confirms its rights to acquire MINVASYS, a France-based cardiovascular disorder solutions specialist, to accelerate its development and to establish as a benchmark in interventional cardiology market.

Moreover, increasing expansion of regional key players in the other regions is also expected to influence the regional market growth. For instance, in April 2018, Terumo Corporation, Tokyo-based medical device company, received CE mark for Ultimaster TANSEI drug-eluting stent, which was launched in the European market in May 2018. Furthermore, the company also aims to expand in Middle East, Latin America, and Asia in the near future.

For More Information On This Report, Please Visit @

Major players operating in the coronary stents market include Boston Scientific Corporation, Abbott, Medtronic plc, B. Braun Melsungen AG, Stentsy SA, Terumo Interventional Systems, Kyoto Medical Planning Co., Ltd., QualiMed, Elixir Medical Corporation, ENDOCOR GmbH, BIOTRONIK SE & Co. KG, Amaranth Medical, Inc. and Arterial Remodeling Technologies SA

Testosterone Replacement Therapy Market Emerging Trend, Outlook and Forecast 2018-2026

Hypogonadism in men is primarily characterized by reduced concentration of serum testosterone, causing decreased libido, erectile dysfunction, loss of body and facial hair, decreased bone density, weakness, decreased lean body mass, increased body fat, fatigue and anemia. Hypogonadism in adult men is often overlooked; even in the presence of associated symptoms, because the hypogonadism men often ignore the symptoms or they attribute them with alternate cause such as ageing.

Request Sample [email protected]

Increasing prevalence of hypogonadism in adult men worldwide is expected to drive growth of the testosterone replacement therapy market. According to the European Association of Urology: 2016 report, in middle-aged men, the incidence of hypogonadism varies from 2.1% to 12.8%. The incidence of low testosterone and symptoms of hypogonadism in men aged 40-79 varies form 2.1% to 5.7%, in Europe. Hypogonadism is more prevalent in older men, in men with obesity, those with co-morbidities, and in men with a poor health status. Furthermore, according to the Therapeutics Advances of Urology Journal: 2016, testosterone has become one of the most widely prescribed medications in the U.S. in 2011.

Many experts says people with type II diabetes mellitus tend to associated with low testosterone level in the blood. Visceral obesity is important cause of insulin resistance, and important feature in type II diabetes. An increased deposition of abdominal adipose tissue in the hypogonadal patients, leads to decrease testosterone concentrations. According to the Indian Journal of Endocrinology and Metabolism, 2017; a study conducted on 900 men with type II diabetes mellitus (T2DM) to evaluate the testosterone deficiency reported that prevalence of hypogonadism in T2DM patients was found to be 20.7%. Moreover, the percentage prevalence of hypogonadism in patients with T2DM was moderate with highest number of patients belonging to age group 50–59 year.

For instance, according to International Diabetes Federation (IDF) Diabetes Atlas: 2017, number of people with diabetes aged between 20 to 79 years in South East Asia region and Western Pacific region in 2017, was 82 million and 159 million, respectively.

Some of the key players operating in the testosterone replacement therapy market include AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Pfizer, Inc., Acerus Pharmaceuticals Corporation, and Perrigo Company plc.

Key players in these market are engaged in product regulatory approval and new product launch strategies to maintain competitive position in the market. For instance, in March 2017, U.S. FDA approved Abbreviated New Drug Application (ANDA) of Perrigo Company plc, for making the generic version of Eli Lilly and Company’s Axiron topical solution, 30 mg/1.5 mL (testosterone topical solution, 30 mg/1.5 mL).

For More Information On This Report, Please Visit @

Endo International Inc. is being an innovative player in the testosterone replacement therapy market, which engaged in launching novel and innovative product in these market. For instance, in March 2015, Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, launched NATESTO (testosterone nasal gel), the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism.

Hyperpigmentation Treatment Devices Market Market Dynamic, Outlook and Forecast 2018-2026

Hyperpigmentation is one of the most common skin problems, which requires non-invasive device-based treatment in severe conditions such as melasma and post-inflammatory hyperpigmentation. Device-based procedures are preferred when topical therapies fail to improve the pigmentation condition. Lasers and intense pulsed light are two of the most preferred device-based treatments for hyperpigmentation. However, sometimes radiofrequency devices, LED devices, and microdermabrasion-based devices are also used in combination.

Request Sample Report:

Hyperpigmentation treatment devices are highly utilized for minimally invasive aesthetic procedures that cures skin problems. According to the report by International Society of Aesthetic Plastic Surgery titled ‘Global Aesthetic Survey Results’ published in 2017, around 14% rise was reported in skin resurfacing procedures worldwide in 2016, which also includes skin spots and pigmentation. According to the same source, around 2,545,922 facial rejuvenation surgeries, which includes hyperpigmentation treatment were conducted worldwide in 2016. This is expected to drive growth of the hyperpigmentation treatment device market.

Furthermore, increasing prevalence of skin related disorders and increasing old age population is expected to result in high demand for hyperpigmentation treatment devices, thereby driving growth of the market. According to a study published in the British Journal of Dermatology, in 2015, around 9.4% of the global population was estimated to be affected by acne. Furthermore, photon-based therapy and laser-based therapy are emerging as new trend in hyperpigmentation treatment, which would contribute to the hyperpigmentation treatment devices market growth.

According to Coherent Market Insights’ analysis, increasing geriatric population will result in high demand for skin resurfacing and removal of dark spots from hyperpigmentation, which is expected to drive growth of the market over the forecast period. According to world population prospects report published in 2017, the global population is moving towards higher age group. In 2017, an estimated 962 Mn people were aged 60 or over in the world, comprising 13% of the global population, which would reach 1.3 Bn by 2025, by growing at a rate of about 3% per year.

The laser based device creates micro-channels with minimal disruption to the outermost layer of the skin, stratum cornium, and leaves the tissues untouched for better permeability and fast healing. In April 2017, BISON MEDICAL’s CYMA clinic CO2 laser system was granted with 510(k) clearance from the U.S. Food and Drug Administration (FDA). It opened up strong market such as the U.S., which has world’s highest number of annual skin cosmetic procedures for this laser system.

For More Information On This Report, Please Visit @

Key players operating in the global hyperpigmentation treatment devices market include Cutera Inc., Hologic, Inc., Lutronic Corporation, Syneron Medical Ltd., Lumenis Ltd., Alma Lasers, Ltd., AMI, Strata Skin Sciences, Inc., BISON MEDICAL, Solta Medical Inc., Lynton Lasers Ltd., EL.En. S.p.A., Sciton, Inc., Fotona D.O.O., and Alma Lasers, Ltd.

Inhalation Anesthesia Market Future Trend, Outlook and Forecast 2018-2026

Inhalational anesthetics, also termed as volatile anesthetic agents, are used for induction and maintenance of general anesthesia and sedation. They are delivered through inhalation, especially in patients where administration of anesthetics through intravenous route and other routes is not feasible. The most common inhalational anesthetics currently in practice are sevoflurane, desflurane, and nitrous oxide. Sevoflurane has rapid onset of action and faster recovery rate. Inhalational anesthetics cause respiratory depression, a decrease in arterial blood pressure, and cerebral metabolic demand along with an increase in cerebral blood flow. The most common side effect of inhalation anesthesia products is nausea. Halogenated anesthesia may induce the dose dependent hepatotoxicity.

Request Sample Copy of this Report @

Increasing number of surgeries worldwide is one of the major factors driving growth of the inhalation anesthesia market. For instance, according to the World Bank statistics, in 2012, around 4511 surgeries per 1, 00,000 people were performed worldwide. Moreover, according to Lancet Commission for Global Surgery report in 2015, around 143 million unmet surgical needs were recorded worldwide, annually.

Moreover, increasing geriatric population is also expected to propel the market growth. It is often inconvenient to administer anesthesia through intravenous route to geriatric patients due to punctured blood vessels and issue with patient compliance. Therefore, inhalation anesthesia may be useful in such cases. According to United Nations’ report: World Population Prospect-The 2017 Revision, worldwide population of people aged over 60 years is projected to increase from 962 million in 2017 (13% of world population) to 1.3 billion by 2030 and will reach to 2.1 billion by 2050.

The report further stated that the population (of people aged over 60 years) is expected to increase at a rate of 3% annually, by 2050, nearly in all regions except Africa which would have 25% or more population of against entire population with age 60 or more. Increased trauma and accidents deaths worldwide would be another factor for growth of the inhalation anesthesia market.

On the basis of geography, the global inhalation anesthesia market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global inhalation anesthesia market over the forecast period. This is owing to increasing investment in the healthcare sector in the U.S. According to Organization for Economic Co-operation and Development data in 2016, the U.S. spends US$ 10,000 per capita in healthcare sector.

For More Information On This Report, Please Visit @

Moreover, increasing number of hospital admissions and subsequent surgical demand, increasing geriatric population, and high trauma incidences are other prominent factors driving growth of the inhalation anesthesia market in North America. According to American Hospital Association report in 2018, around 35,158,934 hospital admissions were recorded in 2017. Moreover, according to a report by National Trauma Institute in 2015, trauma is responsible for the highest number of death in age group 1 to 46 and economic burden due to trauma cases has increased to US$ 671 billion, annually in the U.S., including healthcare costs and lost productivity costs.

Asia Pacific is expected to be the fastest growing region in the global inhalation anesthesia market due to increasing number of trauma and road accidents. According to the World Health Organization’s (WHO) report: Road Safety in the South East Asia Region, published in 2016, road traffic injuries lead to around 316 000 deaths, annually in south East Asia.

Key players operating in the global inhalation anesthesia market include, Baxter International, Inc., Mylan NV, AbbVie, Inc., Hikma Pharmaceuticals, Piramal Healthcare, Halocarbon Products Corporation, Lunan Pharmaceuticals, Maruishi Pharmaceuticals Co. Ltd., Jiangsu Hengrui Medicine Co., Ltd., Neon Laboratories Ltd., and Troikaa Pharmaceuticals Ltd.

Pharma Grade Magnesium Trisilicate Market Opportunities, Dynamic, Outlook and Forecast 2018-2026

Pagnesium trisilicate is an inorganic compound that is used as Active Pharmaceutical Ingredient (API) in an antacid formulations for the treatment of peptic ulcers. The gelatinous silicon dioxide is formed by the reaction of magnesium trisilicate with gastric contents, which protects ulcerated mucosal surfaces and accelerates healing. It is also used as anti-adherent and lubricant in tablet manufacturing process by avoiding sticking of the tablet content to the tablet punches while compressing. Furthermore, it acts as edible oil purifier, which reduces percentage of fat from oil making it reusable. Pharma grade magnesium trisilicate is widely used by restaurants and food industries as anti-caking agent. Properties such as antioxidant, odor absorbent, and decolorizing makes it as a suitable ingredient for cosmetics.

Get a Request Sample of Research Report @

Safe use of magnesium trisilicate as an antacid medication for pregnant and lactating mothers suffering from acidity is expected to propel growth of pharma grade magnesium trisilicate in global market over the forecast period. For instance, National Health Service in June 2014, stated that magnesium containing antacids are safe to use by pregnant and lactating mothers. Their use for dyspepsia and gastro-esophageal reflux is considered to be compatible with breastfeeding. Also, No adverse effects in breastfeeding infants have been reported.

Prohibitions on import of pharma grade magnesium trisilicate in different countries are expected to restrain growth of the pharma grade magnesium trisilicate market over the forecast period. For instance, in February 2017, Nigeria Customs Service (NCS) prohibited import of medicines included under Headings 3003 and 3004, which consists magnesium trisilicate tablets and suspensions as one of the product.

North America region is expected to hold dominant position in pharma grade magnesium trisilicate market, owing to rising prevalence of gastric ulcer caused by H. pylori infection. For instance, Centers for Disease Control and Prevention (CDC) of U.S. statistics 2014, stated that about 30 to 40 percent of people in the U.S. suffer from H. pylori infection, which is associated with gastric ulcer. Thus, this statistics suggests rising demand for antacid, in turn fueling growth of pharma grade magnesium trisilicate market.

For More Information On This Report, Please Visit @

Key players operating in pharma grade magnesium trisilicate market include, Osian Marine Chemicals Pvt.Ltd., Tomita Pharmaceutical Co. Ltd., Vasundhara Rasayan Limited, Meha Chemicals, Par Drugs & Chemicals Pvt. Ltd., Ams Fine Chemicals, and, Elite Chemicals

Virtual Rehabilitation and Telerehabilitation Systems Market Emerging Trend, Outlook and Forecast 2018-2026

Virtual rehabilitation and telerehabilitation system is an equipment used for treatment in numerous programs such as mental health, substance abuse, and educational services for patients in mental hospitals, care homes, and rehabilitation centers. Telerehabilitation services helps the medical professionals to analyze, supervise, consult, and diagnose diseases. Telerehabilitation relates to services delivered by a number of healthcare service providers in medical branches such as physiotherapy, and also used to take follow-up with the clients after discharge. Furthermore, these systems helps to minimize the frequent patient visits to hospitals.

Get Exclusive Sample Copy @

The usage of virtual rehabilitation and telerehabilitation systems is less expensive for both healthcare providers and patients as compared to conventional in-clinic or person-to-person rehabilitation. This has aided in accelerating growth of the market. According to American Congress of Rehabilitation Medicine (ACRM), in 2015 the in-clinic intervention resulted in more expenses than the telerehabilitation intervention (US$ 654.72 per person). Low price of virtual rehabilitation and telerehabilitaion is major factor for increasing adoption of these services and this has propelled growth of virtual rehabilitation and telerehabilitaion system market. Moreover, rehabilitation systems helps to save data for future analysis and for keeping patient’s record into a database. Therefore, this becomes easy for the healthcare providers to keep a log of the progress of the patients.

Rising trend of using computer assisted rehabilitation systems such as training platform (motion base), a virtual environment, a sensor system (motion capture), and D-flow software, is expected to be another major factor aiding in growth of the market. These systems are useful for both diagnostic and therapeutic use. These systems are expected to help patients suffering from strokes or traumatic injuries and patients with disabilities, in improving their sense of balance, coordination, and mobility. Though virtual reality (VR) has been used in physical therapy for nearly a decade, Computer Assisted Rehabilitation Environment (CAREN) offers better growth opportunities for manufacturers. These systems are expected to advance diagnosis and treatment of musculoskeletal and neurological disorders.

For More Information On This Report, Please Visit @

Key players operating in the global virtual rehabilitation and telerehabilitation market include Bridgeway Senior Healthcare, Motekforce Link, GestureTek Inc., Virtualware Group, Motorika Medical Ltd., LiteGait, Doctor Kinetic, Geminus-Qhom, Rehametrics (NeuroAtHome), Brontes Technologies Inc., and Mindmaze.

Bone Growth Stimulator Market 2018: Outlook, Research, Trends and Forecast to 2026

Bone growth stimulators or BGSs are supplemental devices that are worn after a lumbar (low back) or cervical (neck) spine surgery. Bone growth stimulators can be used to assist spinal bone fuse after a failed fusion procedure. Bone growth stimulation for the cervical and lumbar spine has significant benefits after a fusion procedure. Various doctors recommend BGS for post-operative lumbar and cervical cases. A bone growth stimulator sends low intensity electrical signals to the site of fusion. These electrical signals trigger natural bone healing process of the body, which are sometimes impaired in surgery patients. The global demographic scenario is quite diverse. For instance, India is a country with more than half of the population in the youth bracket, whereas China and the U.S. have the maximum geriatric population. Bone growth stimulators have observed an implausible demand in the past few years. The early development of BGS began in the U.S. and the innovation in technology has made developed and sophisticated products to enter the market.

Request Sample Copy of the Report:

According to the International Osteoporosis Foundation, osteoporosis causes around 8.9 million fractures per year that is around one osteoporotic fracture every 3 seconds. Moreover, osteoporosis is expected to affect around 200 million women worldwide. Around 80%, 75%, 70% and 58% of forearm, humerus, hip and spine fractures, respectively, affects women. A fracture, especially in the spinal cord requires bone surgery. Out of these surgeries, a significant number of patients will need bone growth stimulators due to steady recovery. This in turn will drive the growth of the overall bone growth stimulator market during the forecast period.

Some of the factors such as rise in per capita healthcare spending, increase in personal income, and improvement in healthcare sector will boost growth of the market in bone growth stimulator, globally. Nonetheless, a variety of factors such as uncertainty about efficacy, and availability of alternative therapies may hinder the growth of the overall market.

According to the International Osteoporosis Foundation, the number of vertebral fractures that are not recognized is as high 45% in North America, and 46% in Latin America. After a surgery for a vertebral fracture, there is a high risk of requiring hospitalization for another fracture in the following years. To decrease the morbidity rates in patients with a history of bone surgeries, bone growth stimulators are used extensively. As the number of cases is increasing at an alarming rate, so is the need for bone growth stimulators. This will encourage the growth of the global bone growth stimulator market in the forecast period.

As per the International Osteoporosis Foundation, white women aged 50 years are at 16% lifetime risk of occurrence of a vertebral fracture, whereas the percentage is 5 for white men. The staggering percentage of the population with risk of vertebral fracture above the age of 50 will be responsible for increased number of bone surgeries, thereby augmenting the growth of bone growth stimulators. By geography, North America is likely to dominate the bone growth stimulator industry owing to various factors such as consumer awareness about treatments related bone fracture and injury and high healthcare expenditure. Western Europe will follow North America in terms of market share. Availability of advanced public health systems and subsidies, along with high adoption of new technologies such bone growth stimulators in this region are some of the factors for this region’s high market share.

Request Customization:

Some of the companies operating in the bone growth stimulator market in the current scenario are Orthofix International N.V., Aetna Inc., DJO LLC, Smith & Nephew, Zimmer Biomet Holdings Inc., Ossatec Benelux BV, Elizur, Bioventus LLC., Orchid Medical, IGEA S.p.A, and Verve Consulting Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Hearing Protection Devices Market Demands and Growth Prediction, Outlook 2018-2026

Hearing Protection Devices Market: Overview

Hearing loss is the inability to hear any kind of sounds, whereas deafness is the inability to know and understand speech heard even after the sound is amplified. Intense deafness means an individual cannot hear at all, characterized by the inability to detect or identify sound, even at highest volume. According to Hearing Loss Association of American, in 2013, around 20% of the population of the U.S.—approximately 48 million people—reported some level of hearing loss. At an older age of around 65 years, the proportion of hearing loss is 1:3. Around 60% of individuals who experience hearing loss are either part of the workforce or are in an educational settings. In the U.S., 2-3 in every 1,000 children are born with hearing loss, naturally, by either one or both the ears, and around 15% of teenagers have some level of hearing loss.

Browse Global Strategic Business Report:

A study conducted by Noise and Health organization in Accura, Ghana, a total of 101 mill workers were examined and found that 23.7% were identified with the hearing loss symptoms. According to the Bureau of Labor Statistics’ (BLS) Quarterly Census of Employment and Wages, there are of approximately 74% of hearing loss cases in the U.S. due to manufacturing. Furthermore, approximately 12 million workers in the country are involved in the manufacturing sector. Bureau of Labor Statistics’ (BLS) explains that hearing loss is one of the factor of any individual illness among the manufacturing workers. According to Survey of Occupational Injuries and Illnesses, in the U.S., in 2012, hearing loss accounted for 12% or 18, 500 cases of all recordable cases.

This report segments the global hearing protection devices market on the basis of product type, protector, end user, and geography. On the basis of product type, the market is categorized into ear plugs, earmuffs, uniform attenuation earplugs and hearing bands. On the basis of protector, the market is categorized into enclosure, aural insert, super-aural protectors and circum-aural protector. On the basis of end user, the market is categorized into construction, forestry, military, mining, manufacturing, healthcare and others.

Key features of the study:

  • This report provides in-depth analysis of the hearing protecting devices and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2015 as the base year

  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

  • It profiles leading players in the global hearing protection devices market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans

  • The global hearing protection devices market report caters to various stakeholders in this industry, including investors, device/system manufacturers, distributors and suppliers for hearing protection system, research and consulting firms, new entrants, and financial analysts

  • Some of the major players involved in global hearing protection include 3M, Starkey Laboratories India Pvt. Ltd, Honeywell International Inc, Hellberg Safety Ab, Amplifon., Dynamic Ear Company, Centurion Safety Products Ltd., Sonomax Technologies Inc, Siemens Healthcare GmbH, ADCO Hearing Products Inc, and Elvex Corporation and Moldex-Metric Inc.

To know the latest trends and insights prevalent in the hearing protection devices market, click the link below:

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]